The top ten investors in Texas Therapeutics companies include New Enterprise Associates, Venrock, Canaan Partners, and Silicon Valley Bank and others who have collectively done 3,996 deals. The top 20 VC firms also include StartUp Health, Novartis Venture Fund, Morningside Group and their collective deals reach 5,064. The top 50 VC firms dealflow total 6,229 and include other firms such as, S3 Ventures, Texas Venture Labs, and Oxford Finance Corporation.
| Investor Name | Investor Type | Location | Description | Number of Investments |
| New Enterprise Associates | Venture Capital | Menlo Park, California, United States | New Enterprise Associates is a California-based global venture capital firm that funds companies across all investment stages. | 1,269 |
| Venrock | Venture Capital | Palo Alto, California, United States | Venrock is a venture capital firm investing in technology and healthcare companies. | 531 |
| Canaan Partners | Venture Capital | Menlo Park, California, United States | Canaan Partners is a California-based early-stage venture capital firm focused on disruptive technology startups and healthcare companies. | 466 |
| Silicon Valley Bank | Investment Bank | Santa Clara, California, United States | Silicon Valley Bank works with technology, life science, cleantech, venture capital, private equity and premium wine businesses. | 430 |
| Austin Ventures | Venture Capital | Austin, Texas, United States | Austin Ventures is a venture capital firm investing in early stage and middle market companies. | 361 |
| ARCH Venture Partners | Venture Capital | Chicago, Illinois, United States | ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations | 240 |
| Sofinnova Ventures | Venture Capital | Menlo Park, California, United States | Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and | 187 |
| Apax Partners | Private Equity Firm | New York, New York, United States | Private equity investment group, Apax Partners, invest in leveraged and management buy-outs, growth capital and late venture funds. | 175 |
| Correlation Ventures | Venture Capital | San Diego, California, United States | Correlation Ventures finances early, seed, and later stage venture, and debt financing investments and is based in California. | 171 |
| StartUp Health | Accelerator | New York, New York, United States | StartUp Health is a global organization leading the movement to transform health by building a community of Healthcare Transformers. | 166 |
| Novartis Venture Fund | Corporate Venture Capital | Basel, Basel-Stadt, Switzerland | Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms. | 158 |
| Morningside Group | Venture Capital | Shanghai, Shanghai, China | Morningside Group is a private investment group founded in 1986 by the Chan family of Hong Kong. | 140 |
| Mercury Fund | Venture Capital | Houston, Texas, United States | Mercury Fund is an early-stage venture capital firm. With over $200 million under management, Mercury invests in the middle of the U.S. | 119 |
| GE Capital | Corporate Venture Capital | Ottawa, Ontario, Canada | One of General Electric’s largest growth engines, GE Capital Solutions offers lending products, growth capital, revolving lines of credit, | 111 |
| Osage University Partners | Venture Capital | Bala Cynwyd, Pennsylvania, United States | Osage University Partners is a venture capital fund investing in start-ups that commercialize university research. | 95 |
| Square 1 Bank | Venture Debt | Durham, North Carolina, United States | Square 1 Bank is a full-service commercial bank that provides financial services to entrepreneurs and venture capitalists. | 94 |
| CMEA Capital | Venture Capital | San Francisco, California, United States | CMEA Capital caters seed, early, and later stage venture, private equity, and debt financing investments and is based in California. | 94 |
| Hercules Capital, Inc. | Venture Debt | Palo Alto, California, United States | Hercules Capital, a California-based company, lends to technology, life sciences, and sustainable technology companies. | 88 |
| MB Venture Partners | Venture Capital | Memphis, Tennessee, United States | MB Venture Partners is a Tennessee-based venture capital firm that specializes in investments in the life sciences sector. | 86 |
| Burrill & Company | Venture Capital | San Francisco, California, United States | Burrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies. | 83 |
| Texas Venture Labs | Accelerator | Austin, Texas, United States | Housed at the AT&T Executive Education and Conference Center, Jon Brumley Texas Venture Labs (TVL) provides direct links to the | 81 |
| Oxford Finance Corporation | Private Equity Firm | Alexandria, Virginia, United States | Oxford Finance, headquartered in Alexandria, Virginia, is a specialty financial services firm that provides capital exclusively to life scie | 76 |
| RA Capital Management | Venture Capital | Boston, Massachusetts, United States | RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. | 70 |
| Pfizer Venture Investments | Corporate Venture Capital | New York, New York, United States | Pfizer Venture Investments is a venture capital firm. | 64 |
| Deerfield | Venture Capital | New York, New York, United States | Deerfield is an investment management firm, committed to advancing healthcare through investment, information and philanthropy. | 64 |
| Comerica Bank | Investment Bank | Reston, Virginia, United States | Comerica Bank is a Texas-based financial services corporation that specializes in business and retail banking, and wealth management. | 58 |
| Lilly Ventures | Corporate Venture Capital | Indianapolis, Indiana, United States | Lilly Ventures is an Indiana-based venture capital firm that provides investment to companies in the life sciences sector. | 54 |
| S3 Ventures | Venture Capital | Austin, Texas, United States | S3 Ventures is a Texas-based, seed- and early-stage venture capital firm that invests in information technology and life sciences companies. | 48 |
| TriStar Technology Ventures | Venture Capital | Nashville, Tennessee, United States | TriStar Technology Ventures is a Tennessee-based investment firm focused on pre-seed and seed-stage healthcare innovation companies. | 48 |
| Sante Ventures | Venture Capital | Austin, Texas, United States | Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies. | 41 |
| The Column Group | Venture Capital | San Francisco, California, United States | The Column Group is a California-based venture capital firm dedicated to developing biotechnology companies. | 40 |
| Redmile Group | Hedge Fund | San Francisco, California, United States | Hedge Fund that does Early Stage Venture, Later Stage Venture, Private Equity, Debt Financing, and Post Ipo Equity Investments | 37 |
| Rock Springs Capital | Venture Capital | Baltimore, Maryland, United States | Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to | 36 |
| Excel Venture Management | Venture Capital | Boston, Massachusetts, United States | Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond. | 36 |
| Brian Smith | Angel | Austin, Texas, United States | Mr. Smith serves as the managing director of S3 Ventures, an earlier stage venture capital firm with $95M under management. He oversees all of S3′s investments. S3 invests primarily in Texas and the southwest. Brian co-founded the Convergent Investors Fund prior to S3, a $70M early-stage venture capital firm in Texas where he oversaw investments in 10 companies. At age 29, he founded and served as chairman and CEO of Crossroads Systems (Nasdaq: CRDS). He led Crossroads through five rounds of venture, strategic and mezzanine financing and to a successful IPO in 1999. Mr. Smith ran Crossroads as a public company for nearly four years. In this role, he was an early pioneer in Storage Area Networks (“SANsâ€), which are industry standard solutions today. For his efforts, he was awarded the prestigious Ernst & Young Entrepreneur of the Year Award in 2000. He spent the first seven years of his career in electrical engineering positions holding product development roles within the Techno | 35 |
| Celgene | Summit, New Jersey, United States | Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases. | 34 | |
| Alexandria Real Estate Equities | Venture Capital | Pasadena, California, United States | Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry, is the largest owner and pre-eminent | 34 |
| Dan Watkins | Angel | Houston, Texas, United States | Dr. Watkins is a Managing Director of DFJ Mercury, a venture capital firm focused on seed and early-stage investments in the sciences and software sectors in the mid-continent region. He is actively investing in both energy related physical sciences startups and life sciences startups. Prior to co-founding DFJ Mercury, Dr. Watkins was the founder and Managing Partner of A3 Associates, a venture firm focused on seed-stage investments in university and research center-based technology transfer opportunities. Dr. Watkins received his BS in Materials Science and Engineering from Rice University and his MS and Ph.D in Materials Science and Engineering from Carnegie Mellon University. He currently serves on the advisory boards of BioHouston, the Rice Alliance for Technology & Entrepreneurship, and Northwestern University’s Innovation and New Ventures Office. | 34 |
| Foresite Capital | Private Equity Firm | San Francisco, California, United States | Foresite Capital provides growth capital to healthcare leaders that aim to transform patient care. | 32 |
| PTV Healthcare Capital | Venture Capital | Austin, Texas, United States | PTV Healthcare Capital is a Texas-based late-stage venture capital firm dedicated to helping entrepreneurs and global innovation. | 32 |
| Perceptive Advisors | Hedge Fund | New York, New York, United States | Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe. | 30 |
| Boston Scientific | Marlborough, Massachusetts, United States | Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. | 28 | |
| UT Horizon Fund | Venture Capital | Austin, Texas, United States | UT Horizon Fund is a strategic venture capital fund that invests in early- and middle-stage companies. | 24 |
| Texas Wide Open for Business | Government Office | Austin, Texas, United States | Texas Wide Open for Business is a public-private partnership that promotes economic development in Texas. | 23 |
| Jennison Associates | Venture Capital | New York, New York, United States | Jennison Associates has earned a reputation for excellence by fulfilling client investment needs since its founding in 1969. | 21 |
| Health Wildcatters | Accelerator | Dallas, Texas, United States | Health Wildcatters is a mentor-driven seed accelerator focused on improving healthcare by supporting entrepreneurs and healthcare startups. | 19 |
| New Ground Ventures | Venture Capital | Westport, Connecticut, United States | New Ground Ventures is an investment platform established to fund and support breakthrough companies. | 17 |
| venBio Partners | Private Equity Firm | San Francisco, California, United States | venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies. | 17 |
| Ed Mathers | Angel | Washington, District of Columbia, United States | Mr. Mathers joined NEA as a partner in August 2008 after a successful 26 years in the biopharm industry. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc, where he was responsible for leading the company’s venture capital subsidiary, and all business and corporate development activities. In addition, Mr. Mathers was an integral member of the executive team that led to the sale of MedImmune to Astra Zeneca in 2007. Prior to joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in a variety of commercial roles, and started his career at Ortho Pharmaceuticals Corporation, an operating company of Johnson & Johnson. Mr. Mathers currently sits on the Boards of Directors of Intarcia Therapeutics, Inc., Satori Therapeutics and Plexxikon Inc. He earned his bachelor’s degree in | 16 |
| Bill Harrington | Angel | Bala Cynwyd, Pennsylvania, United States | William Harrington serves as Managing Partner at Osage Partners. Bill joined Osage University Partners in 2012. He previously served as a Partner at Three Arch Partners, a venture capital firm with over $1 billion under management. During Bill’s twelve years at Three Arch, he focused on medical device, biotechnology, and healthcare service investing. Bill led investments in and served as a director of nearly twenty healthcare companies, a number of which had their origin as university spinouts. He most recently served on the boards of Cameron Health, Baxano, Voyage Medical, Nevro Corporation, APT Pharmaceuticals, and Centerre Healthcare. Prior to entering venture capital in 1999, Bill spent a decade as an interventional radiologist, working with promising new imaging technologies, medical devices, and minimally invasive surgical procedures. Bill holds an MD from Harvard Medical School, an MBA from UC Berkeley, and a BS in Biology and Chemistry from Tufts University. Bill is a CFA chart | 16 |
| Aju IB Investment | Venture Capital | Yeoksamdong, Seoul-t’ukpyolsi, South Korea | Aju IB Investment is a Korean venture capital firm specialized in providing investments for SMEs across all stages of development. | 13 |
| Baxter Ventures | Corporate Venture Capital | Deerfield, Illinois, United States | Baxter Ventures invests in patient care companies with innovative technologies and is an Illinois-based investment firm. | 12 |
| Remeditex Ventures | Venture Capital | Dallas, Texas, United States | Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. | 12 |
| Danny Janiak | Angel | Danny Janiak is an Associate with the Mercury Fund, where he focuses on developing and originating science-based investment themes and startup opportunities. Prior to joining Mercury, Danny was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community. While at In-Q-Tel, Danny was responsible for the management and oversight of technology development programs in numerous In-Q-Tel portfolio companies. In addition, he was responsible for leading technical due diligence on all potential investment candidates in the advanced materials space. Danny received his B.S. and Ph.D. from the University of Maryland where he was a Future Faculty Fellow and held the Robert E. Fischell Fellowship in Biomedical Engineering. In addition, Danny has been selected to participate in the Kauffman Fellows Program through the Center for Venture Education. Danny is currently a board observer of Mercury Fund portfolio | 12 | |
| Sabby Capital | Venture Capital | Upper Saddle River, New Jersey, United States | Sabby Capital is a New Jersey-based investment advisory firm focused on the healthcare industry. | 11 |
| David Goeddel | Angel | Goeddel co-founded Tularik in November 1991, was Vice President of Research until 1996 and CEO from April 1996 – August 2004, when Tularik was acquired by Amgen. He served as Amgen’s first Senior Scientific Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, Inc. and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is | 11 | |
| Green Park & Golf Ventures | Venture Capital | Dallas, Texas, United States | Green Park & Golf, built on over 50 years of operational and financial experience, seeks investment opportunities that offer above-market | 10 |
| Cancer Prevention and Research Institute of Texas | Austin, Texas, United States | CPRIT is a state agency designed to invest in the most promising cancer prevention, academic research and research opportunities in Texas. | 10 | |
| GreatPoint Ventures | Venture Capital | Chicago, Illinois, United States | GreatPoint Ventures is a unique venture capital company that build and invests in innovative companies that can change the world. | 9 |
| Bryant E. Fong | Angel | San Francisco, California, United States | Mr. Fong is a founding Managing Director at Biomark Capital, a life sciences private equity fund formed in 2013. Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Morphotek, Ceptaris Therapeutics, and Ferrokin Biosciences. Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of life science companies including NEOS Therapeutics, Neurotech Pharmaceuticals, ADMA Biologics (ADMA), Acusphere (ACUS), i2Dx, WaveTec Vision, JHL Biotech, and Nora Therapeutics. Mr. Fong earned his bachelor’s degree with honors in | 9 |
| Nextech Invest | Venture Capital | Zürich, Zurich, Switzerland | Nextech Invest Ltd. is a venture capital and private equity firm specializing in early, mid stage and late stage, and emerging growth | 8 |
| NantWorks | Los Angeles, California, United States | NantWorks combines semiconductor technology, supercomputing and advanced networks to improve healthcare, commerce and digital entertainment. | 7 | |
| Tichenor Ventures | Angel Group | Dallas, Texas, United States | Tichenor Ventures is a financial organization. Nothing is publicly known about the organization other than this announcement. If you have | 7 |
| Dennis Stone | Angel | Dennis has served as a member of the Board of Directors since September 2002. Dennis is Chief Scientific Officer and a Director of Remeditex Ventures LLC. He joined Remeditex in August 2011 from UT Southwestern Medical Center, or UTSW, where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development for UTSW from 1998 until July 2011. He has served on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., and MacroGenics, Inc. In addition, he served as the Chairman of the UT Regents’ Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Fund’s Life Science Commercialization Center. He received his undergraduate training at The University of Texas at Austin and his medical degree from UTSW. | 7 | |
| McHenry T. Tichenor, Jr. | Angel | Mr. Tichenor is a private investor, entrepreneur and philanthropist with broad experience in managing and growing successful businesses. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc., which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. He has also served as a director of several public companies. Mr. Tichenor is currently Executive Director of WWWW Foundation (Quad W), a non-profit organization devoted, in part, to cancer research. He is active on various corporate and university boards, including Belo Corp., the McCombs School of Business Advisory Council at the University of Texas at Austin and the MD Anderson Cancer Center Board of Visitors. | 7 | |
| Michael Powell | Angel | Michael Powell, Ph.D., has served on Ocera’s board of directors since June 2006. Dr. Powell has been a managing general partner of Sofinnova Ventures, a venture capital firm, since 1997. From 1990 to 1997, Dr. Powell served as group leader of drug delivery at Genentech, Inc. From 1987 to 1990, he was the director of product development for Cytel Corporation, a biotechnology firm. He is an adjunct professor at the University of Kansas. Dr. Powell is currently the board president of AVAC (AIDS Vaccine Advocacy Coalition) and a past strategic advisor to OneWorld Health and to the IAVI (International AIDS Vaccine Initiative) Innovation Fund. Within the past five years, Dr. Powell served on the board of directors of each of Trius Therapeutics, Inc. and Orexigen Therapeutics, Inc., each of which is a publicly held company, and currently serves on the board of directors of several private companies, including Ascenta Therapeutics, Labrys Biologics, and Mirna Therapeutics. | 7 | |
| GE Healthcare | Fairfield, Connecticut, United States | GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. | 6 | |
| York Capital Management | Micro VC | New York, New York, United States | JGD Management Corp. doing business as York Capital Management is an employee owned hedge fund sponsor | 6 |
| Eastern Capital | Venture Capital | Atlanta, Georgia, United States | Eastern Capital is a private, commercial lending company headquartered in Atlanta, Georgia. | 6 |
| John Creecy | Angel | Mr. Creecy is Chief Executive Officer and a Director of Remeditex Ventures, LLC, a biomedical investment company that seeks to build a robust biomedical industry in Texas and Colorado by investing in early-stage university projects and start-up companies located in those regions. Prior to joining Remeditex, Mr. Creecy served as President and Chief Executive Officer of Hunt Petroleum Corporation and prior to that was the Chief Operating Officer of the Hodges Companies, Inc. For more than 20 years, Mr. Creecy has served in various board positions within the All Saints Health System in Ft. Worth, Texas, the UT Southwestern Medical Center, and the Baylor Health Systems in Dallas, Texas. In addition to miRagen, Mr. Creecy sits on the boards of the following biomedical industry companies: Apollo Endosurgery, Peloton Therapeutics, BiO2 Medical, VuComp, and BiOptix. Mr. Creecy is a graduate of Texas Tech University with a Bachelor’s Degree in Accounting and holds a Master’s of Science | 6 | |
| Presidio Partners | Venture Capital | San Francisco, California, United States | Presidio Partners, a venture capital firm based in San Francisco, invests in IT, life sciences, and energy technology companies. | 5 |
| CPPIB Credit Investments | Venture Debt | Toronto, Ontario, Canada | CPPIB Credit Investments offers investment in leveraged loans, high yield bonds, mezzanine, and other debt solutions. | 5 |
| Elaine Jones | Angel | Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital. She is responsible for making and managing venture investments for Pfizer and currently manages the PVI investments in Aquinox Pharmaceuticals (Vancouver, British Columbia), Flexion Therapeutics (Boston, MA), Merus B.V. (Utrecht, The Netherlands), and NeuroTherapeutics Pharma (Chicago, IL). Elaine brings 10 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team. Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis an | 5 | |
| Joe Aragona | Angel | Joe Aragona is a founder and General Partner of Austin Ventures. AV has over $3 billion under management and is the most active venture and growth equity firm in Texas and among the most established in the nation. Since joining AV in 1982, Joe has focused on information technology and growth equity investing and has worked with software, communications, semiconductor and service companies. Prior to joining Austin Ventures, Joe earned both his MBA and bachelor’s degree from Harvard University and worked in the Merchant Banking Group of the Bank of Boston and Chemical Bank. Joe was a member of the Board of Directors of the National Venture Capital Association (NVCA) from 1999 – 2006, chaired its Research Committee, and served as Chairman of the Board. Joe is also a member of the Board of Directors of Casa Montessori, an early childhood development center. | 4 | |
| AVG Ventures | Venture Capital | Walnut Creek, California, United States | AVG Ventures seeks to invest in early stage technology companies. | 4 |
| Cowtown Angels | Angel Group | Fort Worth, Texas, United States | Cowtown Angels is a Texas-based financial investment group that supports startups and early stage businesses. | 4 |
| Armen Shanafelt | Angel | Indianapolis, Indiana, United States | Armen Shanafelt brings over 22 years of experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures. Previous to joining Lilly Ventures, Dr. Shanafelt was CSO responsible for the generation of the early biotherapeutic pipeline for Eli Lilly and Company, spanning the therapeutic areas of oncology, endocrine, and neuroscience. During his 7 years with Lilly, the biotherapeutic group delivered over 20 molecules into the clinic, with 80% of these remaining active in clinical development. Dr. Shanafelt received his B.S. Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute, where he studied the structure-function relationships of cytokines and their receptors. He since has held leadership positions of increasing responsibility first with the Biotechnology Unit of Bayer Corporation, where he was directly respon | 4 |
| PSP Investments | Venture Capital | Ottawa, Ontario, Canada | PSP Investments is one of Canada’s largest pension investment managers. | 3 |
| GEOC | Venture Capital | Shanghai, Shanghai, China | A Sino-Israel fund established in 2013 to invest Israel start-ups and help them to penetrate into Chinese market | 3 |
| Boston MedTech Advisors | Dedham, Massachusetts, United States | Boston MedTech Advisors assists medical technology companies and healthcare organizations. | 3 | |
| Elbit Imaging Ltd. | Tel Aviv, Tel Aviv, Israel | Elbit Imaging Ltd is an Israel-based holding company. | 3 | |
| James Eadie | Angel | Austin, Texas, United States | James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio. He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a major in 2008. James received his MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital. | 3 |
| Delaware Street Capital | Hedge Fund | Chicago, Illinois, United States | Delaware Street Capital is a Chicago-based hedge fund sponsor investing in public equity markets. | 2 |
| Chicago Venture Partners | Chicago, Illinois, United States | Chicago Venture Partners, an Illinois-based private equity investment firm, offers buyouts, late stage growth equity investments, and PIPES. | 2 | |
| Ridgeway Capital Partners | Private Equity Firm | Tokyo, Tokyo, Japan | Ridgeway Capital Partners Ltd. is a professional firm that specializes in private equity investments. Comprised of Japanese professionals | 2 |
| Ridgeback Capital Management | Miami Beach, Florida, United States | Ridgeback Capital Management | 2 | |
| Michael S. Brown | Angel | Dallas, Texas, United States | Dr. Brown is Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical School in Dallas. He and his long-time colleague, Dr. Joseph L. Goldstein, together discovered the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. They showed that mutations in this receptor cause Familial Hypercholesterolemia, a disorder that leads to premature heart attacks in one out of every 500 people in most populations. They have received many awards for this work, including the Nobel Prize for Medicine or Physiology (1985), the Albert D. Lasker Prize in Basic Medical Research (1985) and the U.S. National Medal of Science (1988). Dr. Brown is a member of the Board of Directors of Pfizer and Regeneron and a former member of the Science Advisory Board of Genentech. He is also a member of the National Academy of Sciences, the Institute of Medicine, Royal Society (London), the Ass | 2 |
| James Brown | Angel | 2 | ||
| KBI Biopharma | Durham, North Carolina, United States | KBI Biopharma, Inc. (KBI) is a leading development and contract manufacturing organization serving the biopharmaceutical industry. We help | 1 | |
| MD Anderson Cancer Center | Houston, Texas, United States | The MD Anderson Cancer Center is one of the original three comprehensive cancer centers in the United States established by the National | 1 | |
| Rice University | Houston, Texas, United States | Rice University is a private research university focused on providing undergraduate education services. | 1 | |
| Baxalta | Illinois City, Illinois, United States | Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing. | 1 | |
| Crabtree Partners | Venture Capital | Lake Forest, Illinois, United States | Crabtree Partners was added in 2014. | 1 |
| Helsinn Investment Fund | Venture Capital | Monaco, Monaco, Europe | The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need | 1 |
| Essex Capital Corporation | Venture Capital | Santa Barbara, California, United States | Essex Capital acts as a financing source and lessor to credit worthy companies on a nationwide basis, leasing all assets except vehicles | 1 |
| Topspin Fund | Topspin Fund | 1 | ||
| Path4 | Venture Capital | Austin, Texas, United States | venture capital firm that invests in new technologies in the musculoskeletal industry | 1 |
| Mordechay Zisser | Angel | Mr. Zisser serves as Executive President of Elbit Imaging since January 2010 and CEO since July 2012. From 1999-2009 Mr. Zisser has served as Executive Chairman of the board of directors of Elbit Imaging. Mr. Zisser also serves as a director in additional companies held by Elbit Imaging, such as InSightec Ltd., Elbit Ultrasound Ltd. and Elbit Medical Holdings Ltd. As Executive President and formerly Executive Chairman of Elbit Imaging, Mr. Zisser has led, and continues to lead, Elbit Imaging’s core businesses, including real estate, hotels, shopping centers, residential projects, commercial real estate, venture capital investments, and fashion. Mr. Zisser also serves as President and Chairman of the board of directors of Europe-Israel Ltd. since March 1998, and since 1983 the President and Chairman of the board of directors of Control Centers (M.M.S.) Ltd. He has developed major real estate projects in Israel (including the city of Emmanuel, the Herzliya Marina, the Ashkelon | 1 |
